Autoimmune epilepsy: Distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA
- 作者：Yonatan Ganor ; Hadassa Goldberg-Stern ; Tally Lerman-Sagie ; Vivian I. Teichberg and Mia Levite
- 关键词：Antibodies ; Autoimmunity ; Double-stranded DNA (dsDNA) ; Epilepsy ; Glutamate receptor ; GluR3 ; NR2A
- 刊名：Epilepsy Research
- 出版年：2005
- 期刊代码：87_09201211
- 类别：med
- 出版时间：2005
- 卷：65
- 期：1-2
- 页码：11-22
- 文件大小：496 K
摘要
We studied 82 patients with different types of epilepsy and 49 neurologically intact non-epileptic controls, and identified three different subpopulations of epilepsy patients bearing significantly elevated levels of autoantibodies to either GluR3B-peptide of glutamate/AMPA receptor subtype 3 (17/82; 21%of patients), or to a peptide of NR2A subunit of glutamate/NMDA receptors (15/82; 18%), or to double-stranded (ds) DNA, the hallmark of systemic lupus erythematosus (13/80; 16%). Most patients had only one antibody type, arguing against cross-reactivity. Nearly all anti-dsDNA Ab-positive patients did not harbor anti-nuclear autoantibodies. Most patients had no history of brain damage, febrile convulsions, early onset epilepsy, acute epilepsy or intractable seizures. We suggest to measure the ‘autoimmune-fingerprints’ of epilepsy patients for diagnostic and therapeutic purposes.